Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.
T Hedley CarrCarrie AdelmanAlan BarnicleIwanka KozarewaSally LukeZhongwu LaiSally HollisBrian DoughertyElizabeth A HarringtonJinyu KangFred SaadNuria SalaAntoine Thiery-VuilleminNoel W ClarkeDarren HodgsonJ Carl BarrettPublished in: Cancers (2021)
Our results confirm the value of plasma testing for HRRm status when there is insufficient high-quality tissue for multi-gene molecular testing. We show that patients with mCRPC benefit from the combination of olaparib and abiraterone treatment regardless of HRRm status. The combination is currently being further investigated in the Phase III PROpel trial.
Keyphrases
- phase iii
- open label
- prostate cancer
- clinical trial
- placebo controlled
- phase ii
- dna repair
- dna damage
- double blind
- small cell lung cancer
- squamous cell carcinoma
- radical prostatectomy
- study protocol
- genome wide
- mass spectrometry
- atomic force microscopy
- ionic liquid
- high resolution
- fine needle aspiration
- transcription factor
- smoking cessation